EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum

Kyung Ah Woo, Eun Jin Yoon, Ryul Kim, Heejung Kim, Seoyeon Kim, Bora Jin, Seungmin Lee, Yu Kyeong Kim, Hyunwoo Nam, Jee-Young Lee iD

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70788 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 11.10.2025. Verfasst von Kyung Ah Woo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Lewy Body Disease, tau Proteins, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Research Foundation, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study evaluated whether plasma phosphorylated tau‐217 (p‐tau217), amyloid beta (Aβ)42/40, and their combination could serve as biomarkers of Aβ co‐pathology across the Lewy body continuum, where Aβ is frequently observed from prodromal to symptomatic stages. METHODS Individuals with dementia with Lewy bodies (DLB), Parkinson's disease (PD), and their shared prodromal stage, isolated rapid eye movement (REM) sleep behavior disorder (iRBD) underwent plasma sampling, Aβ‐PET, and cognitive testing. RESULTS Higher plasma p‐tau217, lower Aβ42/40, and their interaction were associated with greater Aβ‐PET uptake. Individuals with higher‐than‐median p‐tau217 and lower‐than‐median Aβ42/40 showed the highest Aβ burden. Both biomarkers predicted Aβ‐PET positivity, but only p‐tau217 correlated with cognition. Among 44 iRBD participants followed prospectively, elevated baseline p‐tau217 predicted phenoconversion to overt Lewy body disease. DISCUSSION Plasma p‐tau217 and Aβ42/40 may serve as accessible biomarkers of cerebral Aβ pathology and help identify individuals across the Lewy body continuum who could benefit from Aβ‐targeted therapy. Highlights Plasma phosphorylated tau‐217 (p‐tau217) and amyloid beta (Aβ)42/40 predict cerebral Aβ burden in the Lewy body continuum. Both biomarkers individually show high accuracy for identifying Aβ positron emission tomography positivity. Plasma p‐tau217, but not Aβ42/40, is associated with cognitive performance. Elevated plasma p‐tau217 predicts future phenoconversion in isolated rapid eye movement sleep behavior disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesLewy Body Diseasetau ProteinsParkinson DiseasePeptide FragmentsHumansMaleBiomarkersFemaleAgedPositron-Emission TomographyPhosphorylationREM Sleep Behavior DisorderMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Aβ42/40Parkinson's diseaseblood biomarkersdementia with Lewy bodiesidiopathic/isolated REM sleep behavior disorderp‐tau217

Substanzen

Amyloid beta-Peptidestau ProteinsBiomarkersPeptide Fragmentsamyloid beta-protein (1-42)amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Memory Network Medical Research Center, Seoul National University, Seoul, Republic of Korea.
  • Department of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jee-Young Lee

Förderung

  • the National Research Foundation
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Woo, K. A., Yoon, E. J., Kim, R., Kim, H., Kim, S., Jin, B., Lee, S., Kim, Y. K., Nam, H., & Lee, J. Y. (2025). Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70788

Vancouver

Woo KA, Yoon EJ, Kim R, Kim H, Kim S, Jin B, et al. Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70788

BibTeX
@article{Woo2025,
  author = {Woo, Kyung Ah and Yoon, Eun Jin and Kim, Ryul and Kim, Heejung and Kim, Seoyeon and Jin, Bora and Lee, Seungmin and Kim, Yu Kyeong and Nam, Hyunwoo and Lee, Jee-Young},
  title = {Plasma p‐tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70788}
}
Kostenlos starten →